Catalyst

Slingshot members are tracking this event:

Ionis Pharma (IONS) to finish Phase 2 study of IONIS-FXIrx administered to Patients with End-Stage Renal Disease on Hemodialysis in Fall 2016

Source Link:
https://clinicaltrials.gov/ct2/show/NCT02553889?term=Ionis+Pharmaceutical&recr=Open&no_unk=Y&rank=3

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
IONS
100%
BAYRY
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Update on 9.12.16: Estimated Study Completion Date:November 2016
https://clinicaltria...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Nov 01, 2016
Occurred Source:
http://ir.ionispharma.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=2217775
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Study, End-stage Renal Disease, Hemodialysis, Ionis-fxi, Ionis-fxirx
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.